Molbio Diagnostics IPO
Open Date
10 Aug 2026
Close Date
12 Aug 2026
Open Date
10 Aug 2026
Close Date
12 Aug 2026
Min Investment
Lot Size
Issue Size
Price Range
Subscribed

Founded In
2000
CEO
Sriram Natarajan
Financials of Molbio Diagnostics IPO
| Key Performance Indicators | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating Revenue | 836.56 | 1,020.42 | 1,445.69 |
| Other Income | 4.10 | 7.52 | 9.48 |
Total Income | 840.66 | 1,027.94 | 1,455.17 |
Total Expenses | 657.83 | 820.41 | 1,221.35 |
| Profit Before Tax | 129.64 | 194.43 | 231.14 |
Total Profit | 83.54 | 138.58 | 164.14 |
All figures are in crores (₹)

Utilisation of Proceeds
All figures are in crores (₹)
| Purpose | Amount |
|---|---|
| The company proposes to establish infrastructure for research and development facility, Center of Excellence to be operated by Bigtec, and connected office spaces for employees and consultants. The facility will have approximately 150,000 square feet built-up area to consolidate all R&D functions under one roof. | 106 |
| The company intends to purchase plant, machinery and equipment to facilitate automation at manufacturing units. This includes automatic precision liquid micro-volume filling machines, screening machines, pick & place machines, and product assembly and packing machines to reduce manual dependency and manufacturing costs. | 72 |
| The company proposes to utilize funds for general corporate purposes and business requirements including meeting ongoing contingencies, expenses in ordinary course of business, funding growth opportunities, strategic initiatives, and other purposes as approved by the Board, subject to not exceeding 25% of Gross Proceeds. | - |

- Well placed to address unmet demand in a large and growing molecular diagnostic market with gaining credence of point-of-care testing: The company's 'Truenat' platform enables screening and diagnosis for 30 infectious and non-communicable diseases. The global POCT market stands at USD 29.3 billion and is projected to grow at CAGR of 17.9% between 2025 and 2030 to USD 67.1 billion by 2030.
- Innovative, R&D focused business: The company has strong in-house R&D capabilities with 153 permanent employees including 136 scientists. R&D expenditure was ₹ 874.56 million, ₹ 685.69 million and ₹ 597.77 million in Fiscals 2026, 2025 and 2024 respectively, representing 6.05%, 6.72% and 7.15% of revenue from operations.
- Developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform: The company has developed 'Truenat' platform comprising Trueprep universal nucleic acid extraction device and Truelab analyzer. The platform delivers results in approximately 60 minutes with higher sensitivity and specificity compared to conventional diagnostic methods.
- Scalable business model with strong entry barriers, high proportion of recurring revenues and a growing suite of tests: The company's 'Truenat' platform is a closed system designed to work exclusively with their range of test kits ensuring recurring demand. The company operates in an oligopolistic market with high entry barriers, evidenced by 13 years of R&D to obtain ICMR certification.
- Strategic collaborations and acquisitions enhancing capabilities and offerings: The company acquired 65.47% of Prognosys in March 2023 for radiology capabilities and 60.00% of OptraScan INC in October 2024 for digital pathology solutions. These acquisitions enable end-to-end screening and confirmatory tests for infectious diseases at point-of-care.
- Management team with deep domain expertise and track record of delivering strong financial performance: The company's Promoter and CEO Sriram Natarajan has 35 years of experience in developing diagnostic devices, while CTO Chandrasekhar Nair has 34 years of experience in translational research. The management team has delivered strong financial performance with consistent revenue growth.

